Actinium Pharmaceuticals to Sponsor 4th Annual Summit on

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
180
Actinium Pharmaceuticals to Sponsor 4th Annual Summit on Hematologic Malignancies

NEW YORK, March 16, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc.  (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted therapies for cancers lacking effective treatment options, announced today that the Company is a sponsor of Oncology Meeting Innovations’ 4 th Annual Summit on Hematologic Malignancies, which is being held March 30 th – April 2 nd , 2017 at the Fairmont Chateau Whistler in British Columbia, Canada. Dr. John Pagel, Chief of Hematologic Malignancies at the Swedish Cancer Institute will speak in the Emerging Drugs Showcase session titled, “Radioimmunotherapy in AML: Iomab-B and Actimab-A” on Saturday April 1, 2017.

The 4 th Annual Summit on Hematologic Malignancies brings together translational researchers, clinical researchers and key community oncologists to address the challenges of the rapidly evolving area of oncology. The Summit is intended to foster discussion and debate on the evolution of treatment and features a focused approach towards individual patient populations through case-based discussions.

Actinium’s Executive Chairman, Sandesh Seth said, “Meetings such as this Summit on Hematologic Malignancies are vital as they afford us the opportunity to meet with physicians who are not only investigators in our trials but also physicians who can refer patients to our trials. Actinium is honored to have the opportunity to sponsor this event and we are thrilled that Dr. Pagel will be speaking on behalf of Iomab-B and Actimab-A to this fantastic audience.”

About Actinium Pharmaceuticals, Inc.

Actinium Pharmaceuticals, Inc. is a biopharmaceutical company developing innovative targeted therapies for patients with cancers lacking effective treatment options. Actinium's proprietary platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells safely and effectively. The Company's lead product candidate Iomab-B is designed to be used, upon approval, in preparing patients for a hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. A bone marrow transplant is often the only potential cure for patients with blood-borne cancers but the current standard preparation for a transplant requires chemotherapy and/or total body irradiation that result in significant toxicities. Actinium believes Iomab-B will enable a faster and less toxic preparation of patients seeking a bone marrow transplant, leading to increased transplant success and survival rates. The Company is currently conducting a single pivotal 150-patient, multicenter Phase 3 clinical study of Iomab-B in patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older. The Company's second product candidate, Actimab-A, is currently in a multicenter open-label, 53-patient Phase 2 trial for patients newly diagnosed with AML age 60 and over. Actimab-A is being developed to induce remissions in elderly patients with AML who lack effective treatment options and often cannot tolerate the toxicities of standard frontline therapies. In addition, Actinium is developing Actimab-M, which is being studied in patients with relapsed or refractory multiple myeloma in a Phase 1 clinical trial. Actinium is also utilizing its alpha-particle immunotherapy (APIT) technology platform to generate new drug candidates based on antibodies linked to the element Actinium-225 that are directed at various cancers that are blood-borne or form solid tumors. Actinium Pharmaceuticals is based in New York, NY. To learn more about Actinium Pharmaceuticals, please visit www.actiniumpharma.com and to follow @ActiniumPharma on Twitter please visit, www.twitter.com/actiniumpharma .

Forward-Looking Statements for Actinium Pharmaceuticals, Inc.  

This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Contact: Actinium Pharmaceuticals, Inc. Steve O'Loughlin Vice President, Finance and Corporate Development soloughlin@actiniumpharma.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Africa Tech Festival 2026: A Digital Turning Point

Updated Category News Views 96

Setting the Stage for Digital Advancement in Africa Come mid-November, Cape Town's gonna be buzzing with the clatter of tech titans and financial honchos making their annual pilgrimage to the Africa Tech Festival. This ain't just a conference shindig—with names like Naspers, MTN, Meta, and Amazon on the docket, it's a darn convention shaping the continent's future...

Continue Reading
Caregiving's Financial Impact on Women: Insights from Cinergy

Updated Category News Views 84

Women Caregivers Face Financial Crossroads When it comes down to it, caregiving is one heck of a responsibility, particularly for women. It's about the sacrifices they make, not just in time but in financial security, too. Step away from a job to care for someone, and it's a dicey game you're playing with future income. The Cost of Generosity: Financial Impacts Cindy...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 279

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 421

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
Life Insurance: Evolving with Your Financial Journey

Updated Category News Views 32

Why Life Insurance Isn't Just a 'Set It and Forget It' Life insurance isn't some one-time deal you lock in and toss aside. Mike Newell, an insurance pro, highlights how life's shifts—whether in income, dependents, or debt—should drive tweaks to your coverage. As your life story unfolds, so too should the backbone of your financial security. Early Adulthood: Setting...

Continue Reading
Horizon Capital Hits €200M for Ukraine Resilience

Updated Category News Views 80

An Unprecedented Leap Amidst Uncertainty Right in the middle of rebuilding a nation, Horizon Capital's Catalyst Fund has managed to tap into a well of optimism—or guts, depending on how you look at it. With €200 million already in its pocket out of a €300 million goal, this private equity powerhouse is taking a calculated gamble on Ukraine's economic resilience and...

Continue Reading
Peptide Tracker Refresh Unveils New Planning Features

Updated Category News Views 103

Peptide Tracker's Latest Updates: A Game Changer? I'll tell you what—if you're keeping tabs on your peptide intake like a seasoned gardener checks the soil, Peptide Tracker's fresh versions 3.2.0 and 3.3.0 might just be your new best mates. With the addition of washout scheduling and a robust six-month schedule preview, this isn't just another fancy tech update. It's...

Continue Reading
Pine Tree Bets Big on Tulsa Hills Shopping Center

Updated Category News Views 85

Pine Tree's Latest Move in Retail Real Estate Ya ever watch a company make a move so aligned with its playbook that it feels like a script straight outta the boardroom? That's Pine Tree with its recent snag of Tulsa Hills Shopping Center for a cool $108 million. This ain't just any retail spot; it's a bustling hub nestled within the posh outskirts of Jenks, Oklahoma....

Continue Reading
ISC2 Launches AI Security Academy for Cyber Pros

Updated Category News Views 59

AI-Driven Threats Demand Expert Attention Every corner of the tech world has been blabbering about AI, but when it comes to cybersecurity, it's a whole different beast entirely. ISC2—a nonprofit that I like to think of as the cyber wizards’ guild—just threw a lifeline to cybersecurity folks who are swimming in the deep end of AI. With their shiny new AI Security...

Continue Reading
Rock Tech Uncovers Major Lithium Discovery at Victory

Updated Category News Views 59

Rock Tech's Game-Changer at Victory Folks, we've got a shake-up in the lithium landscape over in Ontario, courtesy of Rock Tech Lithium Inc. They just unearthed something quite promising at their Victory Project: a spanking new spodumene-bearing pegmatite discovery. Now I know, if you're like me, you're thinking, 'What's the angle here?' Well, this isn't just another hole...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring the Future of Fly Play hf. Amid Takeover Talks

Updated Category News Views 224

Understanding the Recent Developments at Fly Play hf. Fly Play hf. is currently navigating through a significant phase in its operational journey. Amid potential takeover discussions, stakeholders are keenly interested in how such a move could reshape the airline's direction. As the aviation industry continues to evolve, Fly Play's adaptability and innovative strategies...

Continue Reading
AvePoint Aims for Dual Listing at Singapore Exchange

Updated Category News Views 275

AvePoint's Ambitious Step Towards Dual Listing AvePoint (Nasdaq: AVPT), renowned as a leader in data security, governance, and resilience, is taking a significant step forward by submitting an application to list its shares on the Singapore Exchange Securities Trading Limited (SGX-ST). This application is set against the backdrop of its existing presence on the Nasdaq...

Continue Reading
Kris Kehl Joins Planet Home Lending to Enhance Services

Updated Category News Views 140

Kris Kehl Joins Planet Home Lending Team Planet Home Lending, a prominent national mortgage lender, is excited to announce the addition of Kris Kehl as a Senior Mortgage Loan Officer in California. With over 22 years of extensive experience in the mortgage industry, Kehl brings a relationship-first approach that prioritizes accessibility, clear communication, and...

Continue Reading
The S&P 500: Understanding Future Market Return Challenges

Updated Category News Views 647

Understanding Future Returns for the S&P 500 Recently, there’s been a surge of interest regarding predictions for future returns of the S&P 500. With insights from financial giants like J.P. Morgan and Goldman Sachs indicating a significantly lower return forecast for the coming decade, it’s essential to delve deeper into these evaluations. The consistent message has...

Continue Reading
Investors Can Seize Winds of Change with enCore Energy

Updated Category News Views 183

Understanding the Opportunity with enCore Energy Corp. Investors are currently presented with a significant opportunity to engage in the ongoing developments at enCore Energy Corp. (NASDAQ: EU). The global landscape is rapidly changing, especially in the energy sector, and enCore is no exception. A class action has been filed on behalf of shareholders who purchased...

Continue Reading